13149-83-2

13149-83-2 structure

Name: PEG 12 cetostearyl ether
Chemical Name: 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
CAS Number: 13149-83-2
Molecular Formula: C₄₀H₈₂O₁₃
Molecular Weight: 771.07
Catalog: Research Areas Others
Create Date: 2016-11-18 02:02:07
Modify Date: 2024-02-04 00:44:36
PEG 12 cetostearyl ether can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs[1].

Name	2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
Synonyms	1-Hydroxy-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-dopentacontan Dodeca-oxyaethylen-glykol-monohexadecylaether 3,6,9,12,15,18,21,24,27,30,33,36-Dodecaoxadopentacontan-1-ol 35-hexadecyloxy-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-pentatriacontan-1-ol

Description	PEG 12 cetostearyl ether can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs[1].
Related Catalog	Research Areas >> Others Signaling Pathways >> Others >> Others
References	[1]. Elder DP, et al. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci. 2016 May 25;87:88-99.